3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
26
Radiotherapy
17
Mitomycin
17
Cisplatin
12
Capecitabine
12
pembrolizumab
10
Cyclophosphamide
9
Radiation
8
Paclitaxel
8
fludarabine
7
Specimen Handling
7
Nivolumab
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Cetuximab
6
Biopsy
6
Papillomavirus Vaccines
5
Drug Therapy
5
dehydroftorafur
4
aldesleukin
4
Vaccines
4
Radiotherapy, Intensity-Modulated
4
Irinotecan
4
Watchful Waiting
3
Taxes
3
Oxaliplatin
3
Observation
3
Light Coagulation
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anus Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled